A novel four-gene of iron metabolism-related and methylated for prognosis prediction of hepatocellular carcinoma

References

• Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380:1450–1462.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(11):394–424.
   PubMedGoogle Scholar
• Shin JW. Molecular targeted therapy for hepatocellular carcinoma: current and future. World J Gastroenterol. 2013;19(37):6144.
   PubMed Web of Science ®Google Scholar
• Kulik LEH. Epidemiology and management of hepatocellular carcinoma. Gastroenterology. 2019;156(2):477–491.
   PubMed Web of Science ®Google Scholar
• Zhang S, Chang W, Wu H, et al. Pan-cancer analysis of iron metabolic landscape across the cancer genome atlas. J Cell Physiol. 2019;235(2):1013–1024.
   PubMed Web of Science ®Google Scholar
• Manz DH, Blanchette NL, Paul BT, et al. Iron and cancer: recent insights. Ann Ny Acad Sci. 2016;1368(1):149–161.
   PubMed Web of Science ®Google Scholar
• Fonseca-Nunes A, Jakszyn P, Agudo A. Iron and cancer risk–a systematic review and meta-analysis of the epidemiological evidence. Cancer Epidem Biomar. 2014;23(1):12–31.
   PubMed Web of Science ®Google Scholar
• Chen Y, Fan Z, Yang Y, et al. Iron metabolism and its contribution to cancer (review). Int J Oncol. 2019;54(4):1143–1154.
   PubMed Web of Science ®Google Scholar
• Huang W, Hsu S, Huang H, et al. MethHC: a database of DNA methylation and gene expression in human cancer. Nucleic Acids Res. 2015;43(D1):D856–D861.
   PubMed Web of Science ®Google Scholar
• Kulis MEM. DNA methylation and cancer. Adv Genet. 2010;70:27–56.
   PubMed Web of Science ®Google Scholar
• Puig S, Ramos-Alonso L, Romero AM, et al. The elemental role of iron in DNA synthesis and repair. Metallomics. 2017;9(11):1483–1500.
   PubMed Web of Science ®Google Scholar
• Shah YM, Xie L. Hypoxia-inducible factors link iron homeostasis and erythropoiesis. Gastroenterology. 2014;146(3):630–642.
   PubMed Web of Science ®Google Scholar
• Oexle H, Gnaiger E, Weiss G. Iron-dependent changes in cellular energy metabolism: influence on citric acid cycle and oxidative phosphorylation. Biochim Biophys Acta. 1999;1413(3):99–107.
   PubMed Web of Science ®Google Scholar
• Dev S, Babitt JL. Overview of iron metabolism in health and disease. Hemodial Int. 2017;21(Suppl 1):S6–S20.
   PubMed Web of Science ®Google Scholar
• Torti SV, Torti FM. Ironing out cancer. Cancer Res. 2011;71(5):1511–1514.
   PubMed Web of Science ®Google Scholar
• Stockwell BR, Friedmann AJ, Bayir H, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell. 2017;171(2):273–285.
   PubMed Web of Science ®Google Scholar
• Shao J, Liu X, Zhu L, et al. Targeting ribonucleotide reductase for cancer therapy. Expert Opin Ther Tar. 2013;17(12):1423–1437.
   PubMed Web of Science ®Google Scholar
• Aye Y, Li M, Long MJC, et al. Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies. Oncogene. 2014;34(16):2011–2021.
   PubMed Web of Science ®Google Scholar
• Morikawa T, Maeda D, Kume H, et al. Ribonucleotide reductase m2 subunit is a novel diagnostic marker and a potential therapeutic target in bladder cancer. Histopathology. 2010;57(6):885–892.
   PubMed Web of Science ®Google Scholar
• Morikawa T, Hino R, Uozaki H, et al. Expression of ribonucleotide reductase m2 subunit in gastric cancer and effects of rrm2 inhibition in vitro. Hum Pathol. 2010;41(12):1742–1748.
   PubMed Web of Science ®Google Scholar
• Liu X, Zhang H, Lai L, et al. Ribonucleotide reductase small subunit m2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers. Clin Sci. 2013;124(9):567–579.
   PubMed Web of Science ®Google Scholar
• Zhou BS, Tsai P, Ker R, et al. Overexpression of transfected human ribonucleotide reductase m2 subunit in human cancer cells enhances their invasive potential. Clin Exp Metastasis. 1998;16(1):43–49.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Li Y, Hao H, et al. Screening hub genes as prognostic biomarkers of hepatocellular carcinoma by bioinformatics analysis. Cell Transplant. 2019;28(1_suppl):76S–86S.
   PubMed Web of Science ®Google Scholar
• Gao J, Chen H, Yu Y, et al. Inhibition of hepatocellular carcinoma growth using immunoliposomes for co-delivery of adriamycin and ribonucleotide reductase m2 siRNA. Biomaterials. 2013;34(38):10084–10098.
   PubMed Web of Science ®Google Scholar
• Lee B, Ha SY, Song DH, et al. High expression of ribonucleotide reductase subunit m2 correlates with poor prognosis of hepatocellular carcinoma. Gut Liver. 2014;8(6):662–668.
   PubMed Web of Science ®Google Scholar
• Yu Y, Wong J, Lovejoy DB, et al. Chelators at the cancer coalface: desferrioxamine to triapine and beyond. Clin Cancer Res. 2006;12(23):6876–6883.
   PubMed Web of Science ®Google Scholar
• Louandre C, Ezzoukhry Z, Godin C, et al. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int J Cancer. 2013;133(7):1732–1742.
   PubMed Web of Science ®Google Scholar
• Yang P, Lin L, Liu T. Sorafenib inhibits ribonucleotide reductase regulatory subunit m2 (rrm2) in hepatocellular carcinoma cells. Biomolecules. 2020;10(1):117.
   PubMed Web of Science ®Google Scholar
• Wu Z, Zhan Y, Wang L, et al. Identification of osalmid metabolic profile and active metabolites with anti-tumor activity in human hepatocellular carcinoma cells. Biomed Pharmacother. 2020;130:110556.
   PubMed Web of Science ®Google Scholar
• Murley LL, Mackenzie RE. The two monofunctional domain of octamericformiminotransferase-cyclodeaminase exist as dimers. Biochemistry-Us. 1995;34(33):10358–10364.
   PubMed Web of Science ®Google Scholar
• Hagiwara H, Tajika Y, Matsuzaki T, et al. Localization of golgi 58k protein (formiminotransferase cyclodeaminase) to the centrosome. Histochem Cell Biol. 2006;126(2):251–259.
   PubMed Web of Science ®Google Scholar
• Labib OH, Harb OA, Khalil OH, et al. The diagnostic value of arginase-1, FTCD, and moc-31 expression in early detection of hepatocellular carcinoma (hcc) and in differentiation between hcc and metastatic adenocarcinoma to the liver. J Gastrointest Cancer. 2020;51(1):88–101.
   PubMed Web of Science ®Google Scholar
• Seimiya M, Tomonaga T, Matsushita K, et al. Identification of novel immunohistochemical tumor markers for primary hepatocellular carcinoma; Clathrin heavy chain and formiminotransferase cyclodeaminase. Hepatology. 2008;48(2):519–530.
   PubMed Web of Science ®Google Scholar
• Chen J, Chen Z, Huang Z, et al. Formiminotransferase cyclodeaminase suppresses hepatocellular carcinoma by modulating cell apoptosis, DNA damage, and phosphatidylinositol 3-kinases (pi3k)/akt signaling pathway. Med Sci Monit. 2019;25:4474–4484.
   PubMed Web of Science ®Google Scholar
• Louet M, Labbé CM, Fagnen C, et al. Insights into molecular mechanisms of drug metabolism dysfunction of human cyp2c9*30. PLoS One. 2018;13(5):e0197249.
   PubMed Web of Science ®Google Scholar
• Senda A, Mukai Y, Hayakawa T, et al. Angiotensin ii receptor blockers inhibit the generation of epoxyeicosatrienoic acid from arachidonic acid in recombinant cyp2c9, cyp2j2 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2017;121(4):239–245.
   PubMed Web of Science ®Google Scholar
• London SJ, Sullivan-Klose T, Daly AK, et al. Lung cancer risk in relation to the cyp2c9 genetic polymorphism among caucasians in los angeles county. Pharmacogenetics. 1997;7(5):401–404.
   PubMedGoogle Scholar
• Martínez C, García-Martín E, Ladero JM, et al. Association of cyp2c9 genotypes leading to high enzyme activity and colorectal cancer risk. Carcinogenesis. 2001;22(8):1323–1326.
   PubMed Web of Science ®Google Scholar
• Chan AT, Tranah GJ, Giovannucci EL, et al. A prospective study of genetic polymorphisms in the cytochrome p-450 2c9 enzyme and the risk for distal colorectal adenoma. Clin Gastroenterol. 2004;2(8):704.
   Google Scholar
• Hu DG, Marri S, Mckinnon RA, et al. Deregulation of the genes that are involved in drug absorption, distribution, metabolism, and excretion in hepatocellular carcinoma. J Pharmacol Exp Ther. 2019;368(3):363–381.
   PubMed Web of Science ®Google Scholar
• Shuaichen L, Guangyi W. Bioinformatic analysis reveals cyp2c9 as a potential prognostic marker for hcc and liver cancer cell lines suitable for its mechanism study. Cell Mol Biol (Noisy-le-grand). 2018;64(7):70–74.
   PubMed Web of Science ®Google Scholar
• Yu D, Green B, Marrone A, et al. Suppression of cyp2c9 by microRNA hsa-mir-128-3p in human liver cells and association with hepatocellular carcinoma. Sci Rep-Uk. 2015;5(1):8534.
   Google Scholar
• Myung SJ, Yoon J, Yu SJ. Stat3 & cytochrome p450 2c9: a novel signaling pathway in liver cancer stem cells. Biomed Pharmacother. 2012;66(8):612–616.
   PubMed Web of Science ®Google Scholar
• Oliveira Alves MG, Carta C, Padín-Iruegas M, et al. Expression of atp6v1c1 during oral carcinogenesis. Biotech Histochem. 2016;91(4):263–268.
   PubMed Web of Science ®Google Scholar
• Cai M, Liu P, Wei L, et al. Atp6v1c1 may regulate filament actin arrangement in breast cancer cells. PLoS One. 2014;9(1):e84833.
   PubMed Web of Science ®Google Scholar
• Mcconnell M, Feng S, Chen W, et al. Osteoclast proton pump regulator atp6v1c1 enhances breast cancer growth by activating the mtorc1 pathway and bone metastasis by increasing v-ATPase activity. Oncotarget. 2017;8(29):47675–47690.
   PubMedGoogle Scholar
• Xu J, Xie R, Liu X, et al. Expression and functional role of vacuolar h+-ATPase in human hepatocellular carcinoma. Carcinogenesis. 2012;33(12):2432–2440.
   PubMed Web of Science ®Google Scholar